First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of SPR720, a Novel Oral Bacterial DNA Gyrase (GyrB) Inhibitor for Mycobacterial Infections

SPR720 (phosphate prodrug of SPR719) is a novel aminobenzimidazole bacterial DNA gyrase (GyrB) inhibitor in development for nontuberculous mycobacterial pulmonary disease (NTM-PD) and pulmonary tuberculosis. SPR719 has demonstrated activity against clinically relevant mycobacteria in vitro and in mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Talley, Angela K., Thurston, Archie, Moore, Grayson, Gupta, Vipul K., Satterfield, Myriah, Manyak, Erika, Stokes, Suzanne, Dane, Aaron, Melnick, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525492/
https://www.ncbi.nlm.nih.gov/pubmed/34491803
http://dx.doi.org/10.1128/AAC.01208-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525492/
https://www.ncbi.nlm.nih.gov/pubmed/34491803
http://dx.doi.org/10.1128/AAC.01208-21

Ejemplares similares